The company aims to revolutionize synthetic biology by creating groundbreaking technologies that enable DNA writing at speed, cost, and quality. Elegen is well-capitalized by top life science investors and staffed by leading biotechnology scientists and entrepreneurs, including Dr. Marc Unger. Dr. Matthew Hill, the company's founder, has a PhD from Stanford and a proven track record of advancing innovative technologies from invention to commercial success.